The most robust clinical evidence for the effectiveness of the monkeypox virus (MPX) vaccine was published today by the U.K. Health Security Agency (UKHSA).
The UKHSA estimates that the two-dose JYNNEOS® (MVA-BN, IMVAMUNE®) vaccine effectiveness for a single dose was 78% fourteen or more days after the initial vaccination.
Monkeypox Vaccine Efficacy Disclosed
Monkeypox Outbreak Recedes in the U.K.
The U.K. Health Security Agency (UKHSA) confirmed today the epidemiological situation of the monkeypox virus outbreak.
Cases of monkeypox (MPX) infection have been confirmed in England since May 6, 2022.
As of November 21, 2022, there were 3,570 confirmed and 150 highly probable monkeypox cases detected in the U.K.
Of these, 96 were in Scotland, 34 were in Northern Ireland, 47 were in Wales, and 3,543 (69%) were in England.
There are no reported deaths in the U.K.
Double Facial Recognition Launches in Real-Time
As the U.S. Transportation Security Administration (TSA) continues deploying innovative technologies in Digital ID, air travelers are enjoying safer and more effortless screening experiences.
For example, catching a flight at Denver's international airport (DEN) requires a new, real-time photo comparison of the traveler.
The TSA recently announced the next generation of Credential Authentication Technology (CAT) verifies the traveler's photo on the credential against the in-person, real-time image.
Outreach Messages Up Well-Child Visits, Vaccination Completion
Rates of scheduling and completion of well-child visits increased regardless of whether messages were standard or tailored